CLYM19150 / EA4181 / Reagan
Research Question:
How do three chemotherapy regimens consisting of bendamustine, rituximab, high dose
cytarabine, and acalabrutinib compare in treating patients with newly diagnosed mantle
cell lymphoma?
Basic Study Information
Purpose:
This phase II trial compares three chemotherapy regimens consisting of bendamustine,
rituximab, high dose cytarabine, and acalabrutinib and studies how well they work
in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy,
such as bendamustine and cytarabine, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Monoclonal antibodies, such as rituximab, may interfere with
the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. This study
is being done to find out if one the drug combinations of bendamustine, rituximab,
high dose cytarabine, and acalabrutinib is better or worse than the usual approach
for mantle cell lymphoma.
Location: University of Rochester Medical Center
Study Reference #: CLYM19150
Lead Researcher (Principal Investigator)
Lead Researcher:
Patrick Reagan
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search